The Royal Free Hospital

London NW3 2QG

2 studies enrolling now · 25 studies all time

What they study most

Active Idiopathic Inflammatory Myopathy, Advanced Cholangiocarcinoma, Antisynthetase Syndrome, Atopic Dermatitis, Cytomegalovirus (CMV) Infection, Dermatomyositis, Enteric Hyperoxaluria, Fabry Disease, Familial Chylomicronemia Syndrome, Gaucher Disease, Gaucher Disease, Type 1, Immune-Mediated Necrotizing Myopathy

Studies at this site

• A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients — Recruiting now
• A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy — Enrolling by invitation
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism — Running, not enrolling
• Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients — Completed
• Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease — Completed
• FlowTriever All-Comer Registry for Patient Safety and Hemodynamics — Completed
• A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults — Running, not enrolling
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension — Completed
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension — Completed
• Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 — Completed
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) — Completed
• Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) — Completed
• A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients — Completed
• Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients — Completed
• Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function — Completed
• Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks — Completed
• Extension Study of PRX-102 for up to 60 Months — Completed
• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis — Stopped early
• Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria — Stopped early
• Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase — Completed
• Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease — Completed
• Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis — Completed
• Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria — Completed